RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
February 18, 2022
RegMed Investors’ (RMi) closing bell: what has changed, an escalation of fears
February 16, 2022
RegMed Investors’ (RMi) closing bell: the sectors back to its losing way
February 16, 2022
RegMed Investors’ (RMi) pre-open: what’s sustainable share pricing in our universe of cell and gene therapy?
February 15, 2022
RegMed Investors’ (RMi) closing bell: a beautiful day in the sector’s neighborhood
February 14, 2022
RegMed Investors’ (RMi) closing bell: interpreting the cell and gene therapy sector’s decline
February 11, 2022
RegMed Investors’ (RMi) closing bell: the week ends with an empty bottle of cell and gene therapy advancements
February 10, 2022
RegMed Investors’ (RMi) closing bell: cell and gene sector gets shot down and crashes in flames
February 8, 2022
RegMed Investors’ (RMi) closing bell: we had a pitcher in this session, the pitcher's nick-name - Algorithm
February 7, 2022
RegMed Investors’ (RMi) closing bell: another bounce, dips got bought yet, the sector could end-up with overbought and volatile bottoms again
February 4, 2022
RegMed Investors’ (RMi) closing bell: Volatility fell, volume was lower in a positive cell and gene therapy sector close
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.